Chemomab Therapeutics Ltd. financial data

Symbol
CMMB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Kiryat Atidim, Building 7, Tel Aviv, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
Anchiano Therapeutics Ltd. (to 3/17/2021), BioCancell Ltd. (to 11/3/2015)
Latest financial report
6-K - Q2 2024 - Aug 21, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 % -70.7%
Debt-to-equity 20.2 % +264%
Return On Equity -101 % -209%
Return On Assets -84.2 % -172%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 284M shares +28.6%
Common Stock, Shares, Outstanding 287M shares +15.8%
Entity Public Float 37.9M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 286M shares +29.1%
Weighted Average Number of Shares Outstanding, Diluted 286M shares +29.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.93M USD -41.7%
General and Administrative Expense 840K USD -73.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.63M USD +54.2%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -3.63M USD +54.4%
Earnings Per Share, Basic 0.01 USD/shares -55.6%
Earnings Per Share, Diluted 0.01 USD/shares -55.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.04M USD -51.5%
Assets, Current 13.5M USD -51.4%
Property, Plant and Equipment, Net 276K USD -18.3%
Operating Lease, Right-of-Use Asset 341K USD +113%
Assets 14.5M USD -49.6%
Employee-related Liabilities, Current 540K USD -71.1%
Accrued Liabilities, Current 2.55M USD +1.72%
Liabilities, Current 4.31M USD -36.9%
Operating Lease, Liability, Noncurrent 251K USD +661%
Liabilities 4.56M USD -33.5%
Retained Earnings (Accumulated Deficit) -96.2M USD -19.4%
Stockholders' Equity Attributable to Parent 9.99M USD -54.6%
Liabilities and Equity 14.5M USD -49.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD -93.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD +506%
Common Stock, Shares Authorized 4.65B shares +615%
Common Stock, Shares, Issued 287M shares +15.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.25M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.11M USD -51.1%
Deferred Tax Assets, Valuation Allowance 43.5M USD +5.53%
Deferred Tax Assets, Gross 43.5M USD +5.53%
Operating Lease, Liability 392K USD +83.2%
Depreciation 16K USD +23.1%
Payments to Acquire Property, Plant, and Equipment 1K USD -92.9%
Lessee, Operating Lease, Liability, to be Paid 464K USD +112%
Property, Plant and Equipment, Gross 529K USD -0.56%
Operating Lease, Liability, Current 109K USD +0.93%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD -8.73%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 72K USD +1340%
Lessee, Operating Lease, Liability, to be Paid, Year Three 121K USD +30.1%
Deferred Tax Assets, Operating Loss Carryforwards 38.3M USD +4.67%
Lessee, Operating Lease, Liability, to be Paid, Year Four 121K USD
Additional Paid in Capital 106M USD +2.32%
Deferred Tax Assets, Net of Valuation Allowance 0 USD